Evidence map›Paper›PMID 36750714›Full record

ArticleScientific reports2023

Magnetic hydrogel particles improve nanopore sequencing of SARS-CoV-2 and other respiratory viruses.

P Andersen, S Barksdale, R A Barclay, N Smith, J Fernandes, K Besse, D Goldfarb, R Barbero, R Dunlap, T Jones-Roe and 16 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Nanopore sequencing in veterinary medicine: from concepts to clinical applications.Frontiers in cellular and infection microbiology · 2025
    Review
  7. Article
  8. Article
  9. Article
  10. Comparison of NanotrapFrontiers in microbiology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 1 institution in 1 country.

P AndersenCeres Nanosciences, Inc., Manassas, VA, 20110, USA. pandersen@ceresnano.com.
S BarksdaleCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
R A BarclayCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
N SmithCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
J FernandesCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
K BesseCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
D GoldfarbCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
R BarberoCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
R DunlapCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
T Jones-RoeCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
R KellyCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
S MiaoCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
C RuhunusiriCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
A MunnsCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
S MosaviCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
L SansonCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
D MunnsCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
S SahooCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
O SwahnCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
K HullCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
D WhiteCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
K KolbCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
F NorooziCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
J SeelamCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
A PatnaikCeres Nanosciences, Inc., Manassas, VA, 20110, USA.
B LepeneCeres Nanosciences, Inc., Manassas, VA, 20110, USA. blepene@ceresnano.com.
Ceres Nanosciences · US

Funding

RADX TECH - CERES NANOSCIENCE INC NANOTRAP PARTICLE MANUFACTURING75N92020C00021 · NHLBI · CERES NANOSCIENCES, LLLP · PI DUNLAP, ROSS · 2021 to 2021
$4.0M
Nanotrap particle viral enrichment technology for enabling portal, next-generation sequencing-based surveillanceR43IP001142 · IP · CERES NANOSCIENCES, LLLP · PI LEPENE, BENJAMIN SCOTT · 2020 to 2020
$244k
ACL HHS R43IP001142NCIRD CDC HHS R43 IP001142NHLBI NIH HHS 75N92020C00021
6 · The paper itself

Abstract

Presented here is a magnetic hydrogel particle enabled workflow for capturing and concentrating SARS-CoV-2 from diagnostic remnant swab samples that significantly improves sequencing results using the Oxford Nanopore Technologies MinION sequencing platform. Our approach utilizes a novel affinity-based magnetic hydrogel particle, circumventing low input sample volumes and allowing for both rapid manual and automated high throughput workflows that are compatible with Nanopore sequencing. This approach enhances standard RNA extraction protocols, providing up to 40 × improvements in viral mapped reads, and improves sequencing coverage by 20-80% from lower titer diagnostic remnant samples. Furthermore, we demonstrate that this approach works for contrived influenza virus and respiratory syncytial virus samples, suggesting that it can be used to identify and improve sequencing results of multiple viruses in VTM samples. These methods can be performed manually or on a KingFisher automation platform.

Indexed as

COVID-19Nanopore SequencingHigh-Throughput Nucleotide SequencingHumansHydrogelsMagnetic PhenomenaSARS-CoV-2Hydrogels

Identifiers

PMID36750714
PMCPMC9903261
OpenAlexW4319437845

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.